Manveo Meningococcal Vaccine, Group A, C, Y & W-135
Save
C, Group A, Meningococcal Vaccine, Y & W-135
Meningococcal Vaccine, Group A, C, Y & W-135 active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Technical Specifications
| Drug Composition | C, Group A, Meningococcal Vaccine, Y & W-135 |
|---|---|
| Variant / Strength | '- |
| Dosage Form / Type | Injectables |
| Product Benefits | Prevention of Meningococcal disease |
| Packaging Type | Vial |
| Delivery Time | 7 - 15 Days, as per delivery location. |
| Country of Origin | Made in India |
| Export Destinations | USA, UK, UAE, Philippines, Thailand, Kenya, Nigeria, Germany, Canada, Mexico, and 65+ more countries |
| Export Route | Shipped via temperature-controlled international air courier with full customs documentation |
Product Overview & Description
The vaccine is employed to guard against meningococcal disease, serving as active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
Submit Quotation Request
Verified Customer Reviews (0)
Frequently Asked Questions
ℹ️ Information reviewed by Medibliss Lifesciences Editorial Team. Last reviewed: August 2026. Data sourced from manufacturer documentation and WHO-GMP certificates.
Disclaimer: The information provided on this page is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Medibliss Lifesciences acts solely as an exporter and supplier. Please consult your physician or a qualified healthcare provider before starting any medication. We do not manufacture these products and rely on the manufacturer's provided documentation and WHO-GMP certifications for product information.